ARS Pharmaceuticals SPRY
NASDAQ SPRY
$4.40 +0.27 (+6.54%)
At close: Sep 29, 2026 · 4:00 PM EDT

ARS Pharmaceuticals (SPRY) EV to EBITDA (2022)

Updated

ARS Pharmaceuticals' EV to EBITDA came in at -2.87 for Q3 2022.

Analysis

ARS Pharmaceuticals (SPRY) EV to EBITDA (2022) Analysis & Trends

Over the trailing twelve months to Sep 30, 2022, ARS Pharmaceuticals reported EV to EBITDA of -24.10.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 ARS Pharmaceuticals 410.68 Mn 266.88 Mn 20.81 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 -2.87
Jun 30, 2022 -9.83
API Access

ARS Pharmaceuticals EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=SPRY&period=max&api_key=YOUR_API_KEY